Profile data is unavailable for this security.
About the company
Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.
- Revenue in USD (TTM)743.25m
- Net income in USD-351.95m
- Incorporated2018
- Employees1.60k
- LocationTilray Brands Inc655 Madison Avenue, 19Th FloorNEW YORK 10065United StatesUSA
- Phone+1 (416) 934-2141
- Fax+1 (416) 934-2141
- Websitehttps://www.tilray.com/
More ▼
Mergers & acquisitions
| Acquired company | TLRY:NSQ since announced | Transaction value |
|---|---|---|
| Truss Beverage Co | -33.08% | -- |
| Anheuser-Busch Cos Inc-Beer & Beverage Brands Portfolio(8) | -22.61% | 85.00m |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.24bn | 297.00 | 206.69 | -- | 44.26 | 4.12 | 0.0852 | 0.0852 | 4.16 | -- | -- | -- | -- | 1,016,067.00 | -- | -16.49 | -- | -18.72 | 87.75 | -- | 2.87 | -53.64 | -- | -- | -- | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.25bn | 58.00 | 24.21 | 1.76 | 13.79 | 9.49 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Soleno Therapeutics Inc | 0.00 | -38.99m | 1.25bn | 33.00 | -- | 7.51 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.26bn | 267.00 | -- | -- | -- | 2.86 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.29bn | 55.00 | -- | 1.97 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Novocure Ltd | 509.34m | -207.04m | 1.31bn | 1.45k | -- | 3.61 | -- | 2.57 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.34bn | 577.00 | -- | 2.41 | -- | 11.44 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.35bn | 1.60k | -- | 0.4033 | -- | 1.82 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.36bn | 642.00 | 79.12 | 3.07 | 17.71 | 2.80 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.39bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.40bn | 121.00 | -- | 2.11 | -- | -- | -3.50 | -3.50 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.44bn | 112.00 | -- | 4.23 | -- | 23.95 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Neumora Therapeutics Inc | 0.00 | -235.93m | 1.44bn | 124.00 | -- | 3.07 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -152.63m | 1.45bn | 142.00 | -- | 3.56 | -- | -- | -2.08 | -2.08 | 0.00 | 5.34 | 0.00 | -- | -- | 0.00 | -33.72 | -26.04 | -36.09 | -27.45 | -- | -- | -- | -- | -- | -- | 0.023 | -- | -- | -- | -12.36 | -- | -- | -- |
| Dynavax Technologies Corp | 232.28m | -6.39m | 1.46bn | 408.00 | -- | 2.33 | -- | 6.29 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Ardelyx Inc | 124.46m | -66.07m | 1.47bn | 267.00 | -- | 8.79 | -- | 11.80 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Data as of Apr 26 2024. Currency figures normalised to Tilray Brands Inc's reporting currency: US Dollar USD
4.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 7.20m | 0.97% |
| BlackRock Institutional Trust Co. NAas of 04 Apr 2024 | 3.53m | 0.48% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 3.40m | 0.46% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.85m | 0.38% |
| Global X Management Co. LLCas of 31 Dec 2023 | 2.47m | 0.33% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.36m | 0.32% |
| Jane Street Capital LLCas of 31 Dec 2023 | 2.31m | 0.31% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.23m | 0.30% |
| Millennium Management LLCas of 31 Dec 2023 | 2.10m | 0.28% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.95m | 0.26% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
